Main menu


Europe's pause of AstraZeneca prompts doubts in Africa

Primary tabs

Europe's pause of AstraZeneca prompts doubts in Africa

KAMPALA, Uganda (AP) — The suspension of the AstraZeneca vaccine in several European countries over the past week could fuel skepticism about the shot far beyond their shores, potentially threatening the rollout of a vaccine that is key to the global strategy to stamp out the coronavirus pandemic, especially in developing nations.

As things stand, it’s either AstraZeneca or nothing for some poorer countries. The vaccine from the Anglo-Swedish drug maker is cheaper and easier to store than many others. It will make up nearly all of the doses shipped in the first half of the year by COVAX, a consortium meant to ensure low- and middle-income countries receive vaccines.

With little other choice, most developing countries that had the AstraZeneca on hand pushed ahead with it even as major countries in Europe suspended its use over the past week after reports that unusual blood clots were found in some recipients of the shot — despite insistence from international health agencies that there was no evidence the vaccine was responsible.

But while governments in Africa and elsewhere expressed their determination to continue using the shot, not everyone is convinced....

 
1 of 10
FILE - In this March 5, 2021, file photo, a hospital security guard receives one of the country's first coronavirus vaccinations using AstraZeneca COVID-19 vaccine provided through the global COVAX initiative, at Kenyatta National Hospital in Nairobi, Kenya. The suspension of the AstraZeneca vaccine in several European countries could fuel skepticism about the shot far beyond their shores, potentially threatening the rollout of a vaccine that is key to the global strategy to stamp out the coronavirus pandemic, especially in developing nations. (AP Photo/Ben Curtis, File)

KAMPALA, Uganda (AP) — The suspension of the AstraZeneca vaccine in several European countries over the past week could fuel skepticism about the shot far beyond their shores, potentially threatening the rollout of a vaccine that is key to the global strategy to stamp out the coronavirus pandemic, especially in developing nations.

As things stand, it’s either AstraZeneca or nothing for some poorer countries. The vaccine from the Anglo-Swedish drug maker is cheaper and easier to store than many others. It will make up nearly all of the doses shipped in the first half of the year by COVAX, a consortium meant to ensure low- and middle-income countries receive vaccines.

ADVERTISEMENT
 

With little other choice, most developing countries that had the AstraZeneca on hand pushed ahead with it even as major countries in Europe suspended its use over the past week after reports that unusual blood clots were found in some recipients of the shot — despite insistence from international health agencies that there was no evidence the vaccine was responsible.

But while governments in Africa and elsewhere expressed their determination to continue using the shot, not everyone is convinced.

“Why should I allow it to be used on me? Are we not human beings like those in Europe?” Peter Odongo, a resident of a town in northern Uganda, told the Daily Monitor newspaper this week.

The East African country has received 864,000 AstraZeneca doses via COVAX so far but had administered fewer than 3,000 by Tuesday. Authorities blamed logistical challenges in transporting the vaccines deep into the country, but newspaper reports cite resistance to the vaccine.

Even before the latest debate over AstraZeneca, vaccine skepticism had been a concern across the world, as many people are hesitant about shots developed in record time. African countries have faced particular hurdles on a continent wary of being a testing ground for the West. Some leaders have pushed back against skepticism, while others, such as those in Burundi and Tanzania, have fed it by appearing to deny the seriousness of COVID-19.

“Unfortunate events” in Europe will ”clearly not be helpful for our public confidence, in building public confidence and trust on the use of that particular vaccine and other vaccines for sure,” John Nkengasong, director of the Africa Centers for Disease Control and Prevention, told reporters Thursday, as he encouraged African countries to continue their vaccinations. ...

 

 

Problem, Solution, SitRep, or ?: 
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.481 seconds.